Predictores clínicos y características angiográficas del infarto agudo de miocardio por embolia sistémica

  1. Adrián Jerónimo Baza 1
  2. Alejandro Travieso González 1
  3. Angela McInerney 1
  4. Breda Hennessey 1
  5. Luis Marroquín 1
  6. María José Pérez Vyzcaino 1
  7. L. Nombela Franco 1
  8. Pilar Jiménez-Quevedo 1
  9. Hernán D. Mejía Rentería 1
  10. Gabriela Tirado Conte 1
  11. Iván Javier Núñez Gil 1
  12. Pablo Salinas Sanguino 1
  13. Fernando Macaya 1
  14. Antonio Fernández-Ortiz 1
  15. Javier Escaned 1
  16. Nieves Gonzalo 1
  1. 1 Servicio de Cardiología, Hospital Clínico San Carlos, Madrid, España
Journal:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Year of publication: 2022

Volume: 4

Issue: 4

Pages: 287-293

Type: Article

DOI: 10.24875/RECIC.M22000286 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: REC: Interventional Cardiology

Abstract

Introduction and objectives: Systemic coronary artery embolism is one of the mechanisms of acute myocardial infarction of nonatherosclerotic origin. However, the epidemiological, clinical, and angiographic profile of this entity has not been properly established yet. Our objective was to describe the clinical characteristics, angiographic features, and prognosis of acute coronary syndromes (ACS) due to systemic embolism (ACS-E), compare them to those due to coronary atherosclerosis (ACS-A), and identify predictive clinical factors of ACS-E. Methods: All consecutive patients with ACS—admitted to a tertiary hospital from 2003 through 2018—were classified as ACS-E (n = 40) or ACS-A (n = 4989), and prospectively recruited on a multipurpose database. Results: Patients with ACS-E were younger (27.5% vs 9.6% were < 45 years old, P < .001), more often women (42.5% vs 22.5%, P = .003), and had higher rates of atrial fibrillation (AF) (40.0% vs 5.3%, P < .001), previous stroke (15.0% vs 3.6%, P < .001), active neoplasms (17.5% vs 6.9%, P =.009), and previous valvular surgery (12.5% vs 0.5%, P < .001). Also, a higher proportion of them were on warfarin (27.5% vs 2.9%, P < .001). The most frequent culprit vessel was the left anterior descending coronary artery in both groups. A percutaneous coronary intervention was attempted in all patients with ACS-A, and in 75.0% of those with ACS-E (P < .001) being successful in 99.1% and 80.0%, respectively. The in-hospital all-cause mortality rate was 15.0% regarding ACS-E, and 4.0% in the control group (P < .001). A multivariate analysis was performed to study the independent predictors of ACS-E, identify AF, previous valvular surgery, and active neoplasms, younger age, and female sex. Conclusions: ACS-E and ACS-A have different clinical and angiographic characteristics. Atrial fibrillation, previous valvular surgery, active neoplasms, younger age, and female sex were all independent predictors of ACS-E.

Bibliographic References

  • 1. Shibata T, Kawakami S, Noguchi T, et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation. 2015;132:241–250.
  • 2. Popovic B, Agrinier N, Bouchahda N, et al. Coronary Embolism Among ST-Segment-Elevation Myocardial Infarction Patients: Mechanisms and Manegement. Circ Cardiovasc Interv. 2018;11:e005587.
  • 3. Kolodgie FD, Virmani R, Finn A V, Romero ME. Embolic Myocardial Infarction as a Consequence of Atrial Fibrillation: A Prevailing Disease of the Future. Circulation. 2015;132:223–226.
  • 4. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237-269.
  • 5. Prizel KR, Hutchins GM, Bulkley BH. Coronary artery embolism and myocardial infarction. Ann Intern Med. 1978;88:155-161.
  • 6. Lacey MJ, Raza S, Rehman H, Puri R, Bhatt DL, Kalra A. Coronary embolism: A systematic review. Cardiovasc Revasc Med. 2020;21:367-374.
  • 7. Cheng JT, Cahill WJ, Foley EF. Coronary embolism. J Am Med Assoc. 1953;153:211-213.
  • 8. Cheng TO. Coronary embolism. Int J Cardiol. 2009;136:1-3.
  • 9. Kotooka N, Otsuka Y, Yasuda S, Morii I, Kawamura A, Miyazaki S. Three cases of acute myocardial infarction due to coronary embolism: treatment using a thrombus aspiration device. Jpn Heart J. 2004;45:861-866.
  • 10. Stoel MG, von Birgelen C, Zijlstra F. Aspiration of embolized thrombus during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2009;73:781-786.
  • 11. Charles RG, Epstein EJ. Diagnosis of coronary embolism: A review. J R Soc Med. 1983;76:863-869.
  • 12. Roxas CJ, Weekes AJ. Acute myocardial infarction caused by coronary embolism from infective endocarditis. J Emerg Med. 2011;40:509-514.
  • 13. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498.
  • 14. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107-114.
  • 15. Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ. 2016;532:h7013.
  • 16. Ruddox V, Sandven I, Munkhaugen J et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1555-1566.
  • 17. Guo XY, Li N, Du X, et al. Atrial fibrillation is associated with an increased risk of myocardial infarction: insights from a meta-analysis. Atherosclerosis. 2016;254:1–7.
  • 18. Bayturan O, Puri R, Tuzcu EM, et al. Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. Eur J Prev Cardiol. 2017;24:373–381.
  • 19. Falanga A, Schieppati F, Russo D. Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. Semin Thromb Hemost. 2015;41:756-764.
  • 20. Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res. 2018;164 Suppl 1:S23-S28.
  • 21. Liu F, Xu Z, Luo J, et al. Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. Front Cardiovasc Med. 20215;8:766377.
  • 22. Chu G, Versteeg HH, Verschoor AJ, et al. Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. Blood Rev. 2019;35:59-67.
Data source: Dialnet